For decades, scientists have focused on amyloid plaques—abnormal clumps of misfolded proteins that accumulate between neurons ...
Notably, microglia spatially associated with amyloid plaques exhibited increased expression of TREM2 and ApoE compared to such cells in non-immunized controls, regardless of whether the treatment was ...
Scientists have long been racking their brains for ways to treat Alzheimer’s disease, the most common type of dementia.
Hosted on MSN18d
Meet The New Drugs That Can Slow Down Early Alzheimer’sBut in just the past year and a half, two anti-amyloid drugs—lecanemab (Leqembi) and donanemab (Kisunla)—have been approved in the U.S. that can slow the progression of early Alzheimer’s disease. The ...
10dOpinion
MedPage Today on MSNHow a Book Is Undermining Progress Against Alzheimer'sSystematic fraud -- led by a "cabal of self-interested researchers, government accomplices, and corporate greed" in the words ...
Not the Same. In amyloid-negative people (left) few tangles accumulate over a decade. In amyloid-positives (right), tangles grow faster in women (red) than men (blue). [Courtesy of Gillian Coughlan, ...
Life Molecular Imaging (LMI) and St. Teresa's Hospital are pleased to announce that Florbetaben (18F) Injection (brand name: Neuraceq®) will be available in Hong Kong from St. Teresa's Hospital by ...
Chicago area scientists have identified the genes that drive the process of Alzheimer’s disease and are working to make the drug Lecanemab even better by identifying which genes are active ...
4d
MedPage Today on MSNBrain Edema, Imaging Abnormalities Reported for Alzheimer's DrugTreatment with donanemab (Kisunla) raised the risk of amyloid-related imaging abnormalities (ARIA) in people with early ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results